Fast And Accurate Detection Of Alzheimer's Disease Targets With SimpleStep ELISA® Kits And SPECTROstar® ^Nano

By Mallori Milligan, Abcam, Scott Detmer, Abcam, and Carl Peters, BMG LABTECH

This content is brought to you by Abcam, a Danaher Operating Company.

Alzheimer’s disease is a multifactorial neurodegenerative condition. Although it is widely acknowledged that this disease leads to progressive dementia, the precise causes and underlying mechanisms remain largely unclear. Various potential therapeutic targets have been identified, but more research is necessary to fully understand their roles in both normal neural function and Alzheimer’s disease to create safe and effective treatments.

This study highlights the detection of three specific targets: Human BDNF (Brain-derived neurotrophic factor), Tau, and TREM2 (Triggering receptor expressed on myeloid cells 2), all of which show altered expression with AD progression. These analytes were assessed using SimpleStep ELISA® kits and detected with the SPECTROstar® Nano microplate reader. SimpleStep ELISA® simplifies traditional ELISA experiments into a semi-homogeneous format, offering a streamlined 90-minute, single-wash protocol. When combined with MARS data analysis, these technologies provide results accurately and rapidly.